{"title": "Nuvaxovid - European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid", "hostname": "europa.eu", "description": "Nuvaxovid", "sitename": "European Medicines Agency", "date": "2021-12-17", "cleaned_text": "Nuvaxovid is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 12 years and older. Nuvaxovid contains a version of a protein found on the surface of SARS-CoV-2 (the spike protein of the virus that causes COVID-19), which has been produced in the laboratory. - List item Nuvaxovid : EPAR - Medicine overview (PDF/181.95 KB) First published: Last 06/07/2023 non-proprietary or common name|| | COVID-19 Vaccine (recombinant, adjuvanted) |Therapeutic area (MeSH)|| | COVID-19 virus infection |Anatomical therapeutic chemical (ATC) code|| | J07BX03 |Additional monitoring|| | This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under |Publication details| issue of valid throughout the European Union|| | 20/12/2021 |Contact II/0048/G This medicine's [product information](/en/glossary/product-information) available in all official EU languages. Select 'available languages' to access the language you need. [Product information](/en/glossary/product-information) contain: [summary of product characteristics](/en/glossary/summary-product-characteristics)(annex I); - manufacturing authorisation holder responsible for batch release (annex IIA); - documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the [Veterinary Medicines Information website](https://www.medicinesinfo.eu/). Pharmacotherapeutic group Vaccines Therapeutic indication Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Assessment history Safety updates - List item COVID-19 vaccines - Safety update: 8 December 2022 (PDF/181.16 KB) First published: 08/12/2022 - List item COVID-19 vaccines - Safety update: 10 November 2022 (PDF/193.65 KB)Adopted First published: 10/11/2022 - List item update: 6 October 2022 (PDF/179.91 KB)Adopted First published: 06/10/2022 - List item update: 8 September 2022 (PDF/194.49 KB)Adopted First published: 08/09/2022 - List item update: 2022 (PDF/198.21 KB)Adopted First published: 14/07/2022 Last updated: 03/08/2022 Rev. 1 - List item COVID-19 vaccines - Safety update: 17 June 2022 (PDF/235.43 KB)Adopted First published: 17/06/2022 - List item update: 12 May 2022 (PDF/203.03 KB)Adopted First published: 12/05/2022 - List item update: 13 April 2022 (PDF/214.65 KB)Adopted First published: 13/04/2022 - List item update: 17 March 2022 (PDF/221.74 KB)Adopted First published: 17/03/2022 - List item update: 17 February 2022 (PDF/212.51 KB)Adopted First published: 17/02/2022 - List item "}